Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy [Volume 37, Issue 3, September 2018, Pages 248–256]

Article information

Kidney Res Clin Pract. 2018;37(4):426-426

Publication date (electronic) : 2018 December 31

doi : https://doi.org/10.23876/j.krcp.2018.37.3.248.corr

Eun Joo Song ¹, Kye Hwa Jeong ², Young Ae Yang ², Jeong-Hoon Lim ², Hee-Yeon Jung ², Ji-Young Choi ², Jang-Hee Cho ², Chan-Duck Kim ², Yong-Lim Kim ², Sun-Hee Park ²

¹Department of Internal Medicine, Daehyun Chumdan Geriatric Hospital, Daegu, Korea

²Division of Nephrology and Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea

Correspondence: Sun-Hee Park, Division of Nephrology and Department of Internal Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea. E-mail: sh-park@knu.ac.kr. ORCID: https://orcid.org/0000-0002-0953-3343

[Related article:] In the above article (https://doi.org/10.23876/j.krcp.2018.37.3.248), there was an error in Figure 3. The authors regret this error, and the corrected figure is now presented below.

Figure 3

Kaplan-Meier analysis of anti-PLA2R antibody level and probability of renal survival (chronic kidney disease stage ≥ 3) (A), cumulative probability of complete remission (B) and spontaneous remission (C).

Anti-PLA2R ab, anti-phospholipase A2 receptor antibody.

The authors would like to apologize for any inconvenience.

Article information Continued

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Figure 3

Anti-PLA2R ab, anti-phospholipase A2 receptor antibody.